Research programme: liver disorder therapeutics - Cypralis/Gilead
Latest Information Update: 21 Sep 2016
At a glance
- Originator Gilead Sciences; Selcia
- Developer Cypralis Limited; Gilead Sciences; Selcia
- Class Small molecules
- Mechanism of Action Peptidylprolyl isomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders